[HTML][HTML] Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3 …

F Ader, M Bouscambert-Duchamp, M Hites… - The Lancet infectious …, 2022 - thelancet.com
Background The antiviral efficacy of remdesivir against SARS-CoV-2 is still controversial.
We aimed to evaluate the clinical efficacy of remdesivir plus standard of care compared with …

[HTML][HTML] Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses

H Pan, R Peto, AMH Restrepo, MP Preziosi… - The Lancet, 2022 - Elsevier
Summary Background The Solidarity trial among COVID-19 inpatients has previously
reported interim mortality analyses for four repurposed antiviral drugs. Lopinavir …

[HTML][HTML] Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial

K Ali, T Azher, M Baqi, A Binnie, S Borgia, FM Carrier… - Cmaj, 2022 - Can Med Assoc
Background: The role of remdesivir in the treatment of patients in hospital with COVID-19
remains ill defined in a global context. The World Health Organization Solidarity randomized …

[HTML][HTML] Efficacy and safety of remdesivir in hospitalised COVID-19 patients: a systematic review and meta-analysis

MT Angamo, MA Mohammed, GM Peterson - Infection, 2022 - Springer
Purpose This review was aimed to synthesise the best available evidence on the
effectiveness and safety of remdesivir in the treatment of moderate to severe COVID-19 …

Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials

A Amstutz, B Speich, F Mentré, CS Rueegg… - The Lancet …, 2023 - thelancet.com
Background Interpretation of the evidence from randomised controlled trials (RCTs) of
remdesivir in patients treated in hospital for COVID-19 is conflicting. We aimed to assess the …

[HTML][HTML] Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Y Wang, D Zhang, G Du, R Du, J Zhao, Y Jin, S Fu… - The lancet, 2020 - thelancet.com
Background No specific antiviral drug has been proven effective for treatment of patients
with severe coronavirus disease 2019 (COVID-19). Remdesivir (GS-5734), a nucleoside …

Clinical efficacy and safety of remdesivir in patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials

CC Lai, CH Chen, CY Wang, KH Chen… - Journal of …, 2021 - academic.oup.com
Objectives We performed a systematic review and network meta-analysis of randomized
controlled trials (RCTs) to provide updated information regarding the clinical efficacy of …

Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post …

S Antinori, MV Cossu, AL Ridolfo, R Rech… - Pharmacological …, 2020 - Elsevier
SARS-CoV-2 is causing an increasing number of deaths worldwide because no effective
treatment is currently available. Remdesivir has shown in vitro activity against coronaviruses …

[HTML][HTML] Remdesivir for the treatment of COVID-19: a systematic review and meta-analysis

TC Lee, S Murthy, O Del Corpo, J Senécal… - Clinical Microbiology …, 2022 - Elsevier
Background The benefits of remdesivir in the treatment of hospitalized patients with COVID-
19 remain debated with the National Institutes of Health and the World Health Organization …

[HTML][HTML] Efficacy and harms of remdesivir for the treatment of COVID-19: A systematic review and meta-analysis

A Piscoya, LF Ng-Sueng, A Parra del Riego… - PloS one, 2020 - journals.plos.org
Background Efficacy and safety of treatments for hospitalized COVID-19 are uncertain. We
systematically reviewed efficacy and safety of remdesivir for the treatment of COVID-19 …